Altria Group, Inc.

Altria Group, Inc. (MO) Market Cap

Altria Group, Inc. has a market capitalization of $114.07B.

Price: $68.31

0.37 (0.54%)

Market Cap: 114.07B

NYSE · time unavailable

CEO: Sal Mancuso

Sector: Consumer Defensive

Industry: Tobacco

IPO Date: 1985-07-01

Website: https://www.altria.com

Altria Group, Inc. (MO) - Company Information

Market Cap: 114.07B|Sector: Consumer Defensive

Company Profile

Operating across the United States through its subsidiaries, Altria Group, Inc. is a prominent manufacturer and marketer of both combustible and oral tobacco items. Its portfolio features cigarettes, primarily under the iconic Marlboro brand, alongside cigars and pipe tobacco mainly offered as Black & Mild. The enterprise further provides an assortment of moist smokeless tobacco products, including Copenhagen, Skoal, Red Seal, and Husky, in addition to its on! brand of oral nicotine pouches. Altria distributes its merchandise chiefly to wholesale partners, such as independent distributors, and directly to substantial retail organizations, including major chain stores. The corporation, founded in 1822, maintains its principal offices in Richmond, Virginia.

Analyst Sentiment

54%
Hold

From 14 Active Polls

1Y Forecast: $72.33

▲ +5.9% Potential Upside

Consensus Target Metrics

Low Bound

$64

Median

$74

High Bound

$79

Average

$72

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$72.33
▲ +5.88% Upside
Low Target
$64.00
-6% Risk
Median Target
$74.00
8% Mid
High Target
$79.00
16% Max
Consensus
Buy
16 / 26 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)114,070120,300110,40196,696111,24598,733101,43488,40486,921
Enterprise Value ($M)136,280142,510131,472117,931133,474122,166122,767110,203110,179
Price to Earnings Ratio (P/E)14.4113.1312.6921.8411.7110.4023.827.269.52
Price/Earnings-to-Growth Ratio (PEG)1.041.850.617.50
Price to Sales Ratio (P/S)5.2219.6920.3419.0421.1918.6622.4517.3116.27
Price to Book Ratio (P/B)-42.81-45.09-34.38-27.61-42.04-30.32-28.90-39.50-25.06
Price to Free Cash Flow Ratio (P/FCF)13.74-818.3749.4930.4236.59570.7137.8226.8533.69
Enterprise Value to Sales (EV/Sales)23.3224.2223.2225.4223.0927.1721.5820.62
Enterprise Value to EBITDA (EV/EBITDA)11.6044.2041.4361.1438.9935.2760.9034.5232.72
Debt to Equity Ratio1.89-9.21-7.66-7.34-9.71-7.59-7.42-11.14-7.25

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALTRIA GROUP INC (MO) — Investment Overview

🧩 Business Model Overview

Altria earns revenue by manufacturing and selling nicotine products through established channels in the United States, primarily cigarettes and smokeless tobacco (and related oral nicotine formats). The value chain is structured around (i) long-term procurement and handling of agricultural inputs (tobacco leaf), (ii) large-scale manufacturing and quality control, and (iii) a distribution network that reaches retailers, wholesalers, and other trade partners.

Consumer demand is characterized by habitual use and nicotine dependence, supporting repeat purchasing. From an economic standpoint, the model converts pricing, product mix, and cost discipline into operating cash flow, which then funds ongoing capital return and strategic investment/income from select holdings.

💰 Revenue Streams & Monetisation Model

Revenue is driven mostly by unit sales of cigarettes and smokeless nicotine products rather than by contract-based subscriptions. Monetisation occurs through the combination of:

  • Pricing and excise-tax pass-through: higher per-pack pricing and the ability to maintain net pricing after regulatory and tax effects.
  • Product mix: relative contribution of cigarettes versus smokeless formats, which can materially influence margins.
  • Input cost management: tobacco leaf costs, processing efficiency, and logistics.

Margin structure is primarily influenced by (i) manufacturing and operating cost intensity at scale, (ii) net pricing versus discounting and trade incentives, (iii) regulatory and legal cost burden, and (iv) the mix shift between cigarette categories and smokeless nicotine products.

A smaller portion of earnings can come from equity income and other investments, which typically behave like “non-operating monetisation” of capital rather than part of core product economics.

🧠 Competitive Advantages & Market Positioning

Altria’s moat is best understood as a blend of Switching Costs, Cost Advantages from Scale, and Regulatory/Legal Friction, reinforced by durable intangible assets (trade marks and consumer familiarity).

  • Switching costs / consumer stickiness: nicotine dependence and entrenched usage patterns create inertia. Competitors can win share, but moving consumers away from established formats generally requires sustained marketing and product adoption—often under a tightly regulated environment.
  • Cost advantages from scale: large manufacturing footprint, procurement know-how, and logistics capacity support lower unit costs and flexibility when input costs or demand shift.
  • Regulatory and legal moat: tobacco is heavily regulated and shaped by longstanding frameworks and enforcement. That creates high compliance and legal-risk costs that new entrants must overcome, limiting effective competition.
  • Intangible assets: brands/trademarks and product formulations support demand continuity and help maintain pricing power relative to generic alternatives.

COMPETITIVE BENCHMARKING:

  • Philip Morris International (PMI): global combustible focus outside the US, with heated-tobacco initiatives. Altria’s competitive emphasis is primarily the US market, where distribution structure and local regulatory dynamics differ.
  • British American Tobacco (BAT): global footprint with broad exposure to multiple nicotine categories and geographic diversification. Altria’s positioning is more US-centric, giving it stronger alignment with domestic channel economics and category mix dynamics.
  • Japan Tobacco (JT) (via ownership of tobacco assets in various markets): global scale but different regional regulatory frameworks and product strategies. Altria competes most directly on the US consumer franchise and local cost/scale efficiencies.

Across these rivals, the key contrast is geographic and channel focus: Altria’s advantage is the depth of its US operating system (manufacturing scale, distribution relationships, and regulatory familiarity) and its ability to manage category transitions within the nicotine market.

🚀 Multi-Year Growth Drivers

Tobacco is a mature market; durable returns tend to come from managing category shift and economic resilience rather than from rapid industry expansion. Over a 5–10 year horizon, growth drivers are typically centered on:

  • Share management within nicotine: maintaining share and net pricing in cigarettes while capturing resilience in smokeless nicotine categories where demand can be less volatile than combustibles.
  • Product evolution under regulation: developing and monetising nicotine alternatives to the extent permitted by regulatory pathways, with an emphasis on scale-ready manufacturing and distribution.
  • Operational efficiency: continuous cost actions in manufacturing, procurement, and logistics to offset volume pressure and input variability.
  • Capital allocation and shareholder yield: converting cash flow into sustained capital return, which can be a meaningful component of total return in mature consumer staples-like industries.

While long-term volumes may face secular headwinds from health policy and changing adult behavior, Altria’s potential for sustained value creation is tied to its ability to defend unit economics, manage mix, and adapt product platforms within the regulatory environment.

⚠ Risk Factors to Monitor

  • Regulatory risk (FDA/US state/federal actions): marketing authorization requirements, product standards, flavor restrictions, and other constraints can alter the viable product set and demand patterns.
  • Litigation and legal cost exposure: ongoing and future legal developments can pressure earnings and cash flows.
  • Excise taxes and pricing constraints: changes to tax policy can compress margins depending on the timing and degree of pass-through.
  • Illicit trade: revenue dilution and margin pressure can occur when counterfeit or untaxed products penetrate distribution channels.
  • Input cost volatility: tobacco leaf and related agricultural inputs can move through supply cycles, affecting cost of goods sold.
  • Category displacement: shifts toward regulated nicotine alternatives could reduce combustible demand faster than management assumptions, affecting long-term mix and earnings power.

📊 Valuation & Market View

Equity valuation for tobacco companies typically reflects durable cash generation, capital-return capacity, and the balance between pricing power and volume durability. Investors often benchmark using EV/EBITDA and earnings multiples where appropriate, but the fundamental market narrative usually centers on:

  • Free cash flow durability under regulatory and tax regimes
  • Net pricing trends and mix between cigarettes and smokeless formats
  • Legal and regulatory cost trajectory
  • Balance sheet and capital allocation (including dividend policy and buyback capacity)

Because the business is mature, multiple expansion typically requires evidence of sustained operating leverage and improved risk visibility, while downside risk often emerges from regulatory/legal shocks or faster-than-modeled category displacement.

🔍 Investment Takeaway

Altria’s long-term thesis rests on a resilient US nicotine operating system supported by consumer stickiness (switching inertia), scale-driven cost advantages, and regulatory/legal friction that increases barriers for effective competitive entry. The core challenge is navigating structural category change under stringent regulation; value creation depends on defending net pricing and mix, executing cost discipline, and adapting product strategy within permitted markets.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for MO.

seekingalpha.com2026-08-01

Altria Among 7 Dividend Kings To Announce Annual Dividend Increases In August

Altria Group is poised to announce its 56th consecutive annual dividend increase in August, with a predicted 3.7–4.7% boost to $4.40–$4.44. MO continues its transformation toward non-tobacco nicotine products, targeting mid-single-digit EPS and dividend growth through 2028 despite ongoing cigarette sales declines. Predicted forward yield for MO is 6.44–6.50%, underpinned by a 5-year compounded dividend growth rate of 4.1% and consistent EPS delivery.

247wallst.com2026-08-01

5 Safe Monthly Pay Dividend Stocks Boomers Love in August

Boomer income investors are entering August 2026 with a tricky setup. The 10-year Treasury yield sits at 4.67%, near its 12-month high of 4.71%, while CPI is running in the 81.8th percentile of its 12-month range and the 2026 Social Security COLA has already been baked in at 2.8%.

defenseworld.net2026-08-01

Bank of America Corp DE Sells 823,167 Shares of Altria Group, Inc. $MO

Bank of America Corp DE cut its position in shares of Altria Group, Inc. (NYSE: MO) by 5.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,099,821 shares of the company's stock after selling 823,167 shares during the period.

marketbeat.com2026-07-31

Altria Group Q2 Earnings Call Highlights

Altria Group NYSE: MO reported higher adjusted earnings for the second quarter and first half of 2026, supported by pricing in its smokable-products business, growth in its nicotine pouch portfolio and continued shareholder returns. The company raised the lower end of its full-year adjusted earnings guidance while citing ongoing pressure on nicotine consumers from inflation and elevated gas prices.

prnewswire.com2026-07-31

Altria Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Altria Group (MO)

Levi & Korsinsky is investigating whether Altria Group misdescribed the FDA regulatory status of its on! PLUS nicotine pouch product and the likelihood of near-term FDA authorizations for additional applications.

zacks.com2026-07-31

Sin Stocks: Why Investors Continue to Bet on Controversial Companies

Sin stock sectors, including alcohol, tobacco, cannabis, firearms and gambling, attract investors with resilient cash flows, pricing power and defensive demand despite regulatory, litigation and ESG risks.

zacks.com2026-07-31

Altria Q2 Earnings Call Highlights Smoke-Free Growth Plans

MO highlights on! PLUS expansion, smoke-free growth plans and shareholder returns as it narrows 2026 earnings outlook.

seekingalpha.com2026-07-30

Altria Group, Inc. (MO) Q2 2026 Earnings Call Transcript

Altria Group, Inc. (MO) Q2 2026 Earnings Call Transcript

zacks.com2026-07-30

Altria Q2 Earnings Miss Estimates, Cigarette Volumes Down

MO's second-quarter earnings miss estimates as cigarette shipments fall, though higher pricing lifted smokeable products revenues and supported profit growth.

fool.com2026-07-30

Why Altria Stock Is Sinking Today

Altria posted an earnings miss in the second quarter. The company posted modest sales growth in Q2, but concerns about shipment volumes for cigarettes are weighing on the business's outlook.

benzinga.com2026-07-30

Altria Stock Drops: Inflation Forces Smokers to Ditch Marlboros

Altria Group, Inc. (NYSE:MO) stock slid on Thursday after the company's mixed quarterly results. Inflationary pressure and weaker discretionary spending pushed some smokers toward cheaper cigarette options, weighing on premium brands such as Marlboro.

zacks.com2026-07-30

Altria (MO) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Altria (MO) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com2026-07-30

Altria (MO) Q2 Earnings and Revenues Lag Estimates

Altria (MO) came out with quarterly earnings of $1.48 per share, missing the Zacks Consensus Estimate of $1.5 per share. This compares to earnings of $1.44 per share a year ago.

wsj.com2026-07-30

Altria Profit Falls on Softer Oral-Tobacco Performance

Altria Group had virtually flat revenue and lower profit in the second quarter, as lower sales of its nicotine pouches offset some of the growth in its cigarettes business.

businesswire.com2026-07-30

Altria Reports 2026 Second-Quarter and First-Half Results; Narrows 2026 Full-Year Earnings Guidance

RICHMOND, Va.--(BUSINESS WIRE)---- $MO #Altria--Altria Reports 2026 Second-Quarter and First-Half Results; Narrows 2026 Full-Year Earnings Guidance.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"MO reported Q2’26 revenue of $6.11B and net income of $2.30B (EPS $1.37). On a YoY basis, revenue rose from $5.29B in Q2’25 to $6.11B in Q2’26 (+15.5%), while net income increased from $2.38B to $2.30B (-3.4%). On a QoQ basis, revenue grew from $5.43B in Q1’26 to $6.11B in Q2’26 (+12.5%), but net income dipped from $2.18B to $2.30B (+5.3%). Profitability improved on operating strength but shows volatility in bottom-line translation: gross margin increased versus Q1’26 (74.9% vs 64.6%), and net margin edged down slightly versus Q1’26 (37.6% vs 40.2%). Over the last four quarters, gross margin peaked in the mid-70% range with net margins generally much higher in Q3/Q2 (mid-to-high 40s) than in Q4 (22.0%), followed by a rebound in Q1/Q2. Cash flow quality weakened in the latest quarter: operating cash flow was roughly flat-to-negative (-$0.05B) and free cash flow was -$0.15B, contrasted with strong OCF in Q4’25 and Q1’26. Shareholder returns appear supported mainly by dividends: dividends paid were $1.54B in Q2’26 and payout ratio was ~67%. Total shareholder return is mixed—price is up +12.1% over 1Y (no >20% momentum). Balance sheet resilience remains a concern given negative total equity (about -$2.6B) despite substantial cash ($2.37B) and higher leverage (net debt ~ $45.1B)."

Revenue Growth

Good

QoQ revenue up +12.5% (Q1’26 $5.43B to Q2’26 $6.11B) and YoY up +15.5% (Q2’25 $5.29B to Q2’26 $6.11B), indicating solid top-line momentum.

Profitability

Neutral

Gross margin expanded sharply QoQ (74.9% vs 64.6%), and operating income rose QoQ, but net income was down YoY (-3.4%) and net margin eased slightly QoQ (37.6% vs 40.2%), signaling some earnings volatility.

Cash Flow Quality

Caution

Latest quarter OCF was slightly negative (-$0.05B) and free cash flow was -$0.15B, a sharp deterioration versus Q1’26 (+$2.32B OCF, +$2.23B FCF) and Q4’25 (+$3.27B OCF).

Leverage & Balance Sheet

Neutral

Net debt remains high (~$45.1B) and total equity is negative (about -$2.6B), though cash increased QoQ to $2.37B. Leverage pressure and weak equity cushion reduce resilience.

Shareholder Returns

Positive

Dividends remain meaningful (dividends paid $1.54B; dividend yield ~1.28% per provided ratio data) and buybacks continued ($0.22B repurchased). Price momentum is positive but below strong-trend threshold (+12.1% 1Y).

Analyst Sentiment & Valuation

Neutral

Provided consensus target (~$72.33) is moderately above the current price ($64.17), implying some upside, but the dataset does not indicate >20% 1Y momentum or clear valuation re-rating strength.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Altria’s Q2 2026 showed steady earnings momentum with adjusted diluted EPS of $1.48 (+2.8%) and first-half growth of 4.9%, supported by solid smokeable pricing and disciplined portfolio mix management. The company raised full-year 2026 adjusted EPS guidance to $5.61–$5.72, but management repeatedly anchored the second-half path on consumer pressure (inflation and elevated gas prices) and the timing of duty drawback benefits. Smokeable performance was helped by Marlboro’s strength in premium (59.6% of premium, +0.1 pp sequentially) and Basic’s targeted discount participation without accelerating the category. In smoke-free, Helix expanded on! PLUS to 120,000 stores and reported share gains alongside early trial/repeat signals; however, Oral Tobacco adjusted OCI declined 8% in Q2 due to investments and difficult comps. E-vapor commentary remained supportive of harm reduction given enforcement and regulatory clarity, but illicit prevalence remains an ongoing headwind.

AI IconGrowth Catalysts

  • Helix on! PLUS expansion to 120,000 stores; early data indicates increased trial/volume and repeat purchase rates
  • Helix resumed shipments of on! PLUS 12-milligram in 3 flavors in Florida, North Carolina and Texas; national expansion planned for Q3
  • Helix plans flavor extensions across 6/9/12-milligram strengths beginning with Blueberry Mint and Mango Pineapple in Q4
  • PM USA smokeable portfolio momentum: Marlboro Cowboy Cut early market engagement plus Basic discount traction

Business Development

  • Helix retail trade program securing premium visibility and incremental fixture space for on! PLUS (about 90% of on! PLUS volume covered)
  • AGDC (Altria Group Distribution Company) referenced as supporting on! PLUS retail sell-in
  • Regulatory/enforcement: Minnesota Attorney General lawsuit against a leading illicit e-vapor manufacturer; commerce/payment platforms restricting illicit e-vapor sales; Customs and Border Patrol actions tied to NJOY ACE patent modifications

AI IconFinancial Highlights

  • Adjusted diluted EPS: +2.8% to $1.48 in Q2; +4.9% to $2.80 in first half
  • Adjusted diluted EPS guidance: raised lower end; full-year 2026 outlook set to $5.61–$5.72 vs 2025 base $5.42 (growth 3.5%–5.5%)
  • Return of capital in first half: nearly $3.9B dividends + share repurchases combined
  • Adjusted OCI: +2.4% to $3.0B in Q2; +4.2% to $5.7B in first half; adjusted OCI margins 64.8% (Q2) and 64.9% (first half)
  • Cigarette volume moderation continues: reported domestic cigarettes -3.2% (Q2) and -2.8% (1H); adjusted for trade inventory -4.5% (Q2) and -4.0% (1H); industry (inventory-adjusted) -5% in both Q2 and 1H
  • Oral Tobacco: adjusted OCI -8% (Q2) and -4.2% (1H) due to tough comps and investments behind on! PLUS trial offers; OCI margins 66.7% (Q2) and 67.0% (1H)
  • Nicotine pouch dynamics: nicotine pouch category estimated +6% over past 6 months; category grew 8.1 share points to ~60% of total oral category

AI IconCapital Funding

  • Share repurchases in first half: 5.3 million shares for $335 million
  • Remaining authorization: $665 million under current repurchase program expiring end of year
  • Debt-to-EBITDA: 1.9x at June 30 vs ~2.0x target
  • Board discretion reiterated for future dividend payments and repurchases

AI IconStrategy & Ops

  • Smoke-free: advance Helix on! PLUS via trial-generation, responsible marketing (retail/live events/paid social), and retail trade program
  • Smokeable RGM: continue data-driven precision for Basic; expanded targeted promotional support to ~35,000 stores while refining investment levels
  • PM USA portfolio mix: insulate premium performance (Marlboro premium segment share 59.6%, +0.1 pp sequentially; Basic supports discount where relevant without accelerating category growth)
  • E-vapor harm reduction: emphasize efficient authorization process plus consistent enforcement to create a level playing field; continued focus on illicit supply disruptions

AI IconMarket Outlook

  • Full-year 2026 adjusted diluted EPS guidance: $5.61–$5.72 (3.5%–5.5% growth vs $5.42 base); guidance narrowed and lower end raised
  • Duty drawback/FET expectations: export volume and related tax refunds expected higher in 2H, with more balanced benefit across Q3 and Q4

AI IconRisks & Headwinds

  • Consumer remains under pressure (elevated gas prices, persistent inflation) affecting category demand and cigarette volume dynamics
  • Intensifying nicotine pouch competition (new products/flavors from competitors) while regulatory authorization timelines remain uncertain
  • Oral Tobacco profitability pressure from investments behind on! PLUS trial offers and unfavorable prior-year comparisons (adjusted OCI -8% in Q2)
  • E-vapor illicit market remains prevalent; reliance on continued enforcement to moderate illicit growth and support regulated category expansion

Q&A: Analyst Interest

  • Second-half phasing: Management explained the 2H outlook depends on consumer financial health plus incremental investment needs for on! PLUS expansion (national 12mg) and flavor extensions, while noting they feel confident narrowing guidance after stronger-than-expected first half.
  • Double duty drawback timing + sustainability: Management attributed the lack of sequential FET credit improvement to timing (credit application timing) and product/inventory staging, expecting higher export volumes and a more balanced Q3/Q4 benefit; smokeable OCI strength was driven by Marlboro price realization and Basic contribution.
  • on! PLUS consumer sourcing + retention: Management stated on! PLUS share rose +0.8 pp sequentially and +0.3 pp YoY, describing it as incremental to on! while also drawing MST consumers; they emphasized the pipeline (12mg in Q3; flavors in Q4) and clarified that shipments reflected prior comp/inventory movement.

Sentiment: MIXED

Note: This summary was synthesized by AI from the MO Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for MO.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (MO)

© 2026 Stock Market Info — Altria Group, Inc. (MO) Financial Profile